Sales of Nubeqa (darolutamide), a drug developed jointly by Orion Corporation and Bayer, for the treatment of non-metastatic hormone-resistant (castration-resistant) prostate cancer (nmCRPC), have begun in the European Union and Japan.

For the first commercial sale in the EU, Orion will receive a milestone payment of EUR 20 million from Bayer and for the first commercial sale in Japan EUR 8 million, which Orion will record in its second quarter 2020 results. The entry has no effect on Orion's outlook for 2020, as these milestone payments totaling EUR 28 million have been included in the company's financial guidance.

Contact:

Tuukka Hirvonen

Tel: +358 10 426 2721

Web: www.orion.fi

Orion is a Finnish pharmaceutical company a builder of well-being that operates worldwide. Orion develops, manufactures and markets human and veterinary medicines as well as active pharmaceutical ingredients. The company constantly invests in research and development of new drugs and treatments. The core therapeutic areas of Orion's pharmaceutical research are central nervous system diseases, cancer diseases, rare diseases of the Finnish genetic heritage and respiratory diseases for the treatment of which Orion develops inhaled Easyhaler lung drugs. Orion's net sales in 2019 were EUR 1,051 million, and the company employed about 3,300 people at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

(C) 2020 Electronic News Publishing, source ENP Newswire